Multi-drug-resistant tuberculosis cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Changes made per Mahshid's request) |
||
| (6 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Multi-drug-resistant tuberculosis}} | {{Multi-drug-resistant tuberculosis}} | ||
{{CMG}}; {{AE}} {{AL}} | |||
==Overview== | |||
Treatment of tuberculosis must be analysed for relative cost effectiveness of inpatient and outpatient models of care as it will benefit regions where tuberculosis is highly prevalent. Unless there is severe complications it is highly recommended to treat the TB patient in ambulatory care rather than inpatient services.<ref name="pmid22070215">{{cite journal| author=Fitzpatrick C, Floyd K| title=A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis. | journal=Pharmacoeconomics | year= 2012 | volume= 30 | issue= 1 | pages= 63-80 | pmid=22070215 | doi=10.2165/11595340-000000000-00000 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22070215 }} </ref> | |||
==Cost-effectiveness of therapy== | |||
* According to WHO, tuberculosis takes an annual economic toll of around US$12 billion dollars worldwide. 3-4 months of work time are lot due to tuberculosis. | |||
*The average cost of treating a person with TB disease increases with greater resistance. | |||
*Direct costs (in 2010 U.S. dollars) average from $17,000 to treat drug-susceptible TB to $430,000 to treat the most drug-resistant form of the disease (XDR TB). <ref name="CDC"> {{cite web| url=http://www.cdc.gov/tb/topic/drtb/default.htm| title= CDC Drug-Resistant TB}}</ref> | |||
*When including productivity losses (e.g., lost income) experienced by patients while undergoing treatment, costs are even higher.<ref name="CDC"> {{cite web| url=http://www.cdc.gov/tb/topic/drtb/default.htm| title= CDC Drug-Resistant TB}}</ref> | |||
{| | |||
|[[File:The Costly Burden of MDR-TB.jpg|thumb|550px|left|Image obtained from CDC<ref name="CDC"> {{cite web| url=http://www.cdc.gov/tb/topic/drtb/default.htm| title= CDC Drug-Resistant TB}}</ref>]] | |||
|} | |||
*The cost of [[MDR-TB]] treatment is upto 100 times more expensive than fully sensitive patients.<ref name=Strategies against multidrug-resistant tuberculosis>{{cite web | title = Strategies against multidrug-resistant tuberculosis| url =http://erj.ersjournals.com/content/20/36_suppl/66s.full}}</ref> | |||
*[[DOTS-Plus]] is a cost effective approach in areas of assumed poor compliance. | |||
*Reduced price second line drugs must be given to the programs following the guidelines of "Green Light Committee". This could save upto 57.5% of overall budget for [[TB]] control. <ref name="pmid11463877">{{cite journal| author=Gupta R, Kim JY, Espinal MA, Caudron JM, Pecoul B, Farmer PE et al.| title=Public health. Responding to market failures in tuberculosis control. | journal=Science | year= 2001 | volume= 293 | issue= 5532 | pages= 1049-51 | pmid=11463877 | doi=10.1126/science.1061861 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11463877 }} </ref> | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Bacterial diseases]] | [[Category:Bacterial diseases]] | ||
[[Category:Pulmonology]] | [[Category:Pulmonology]] | ||
[[Category:Tuberculosis]] | [[Category:Tuberculosis]] | ||
Latest revision as of 18:06, 18 September 2017
|
Multi-drug-resistant tuberculosis Microchapters |
|
Differentiating Multi-drug-resistant tuberculosis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Multi-drug-resistant tuberculosis cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Multi-drug-resistant tuberculosis cost-effectiveness of therapy |
|
FDA on Multi-drug-resistant tuberculosis cost-effectiveness of therapy |
|
CDC on Multi-drug-resistant tuberculosis cost-effectiveness of therapy |
|
Multi-drug-resistant tuberculosis cost-effectiveness of therapy in the news |
|
Blogs on Multi-drug-resistant tuberculosis cost-effectiveness of therapy |
|
Directions to Hospitals Treating Multi-drug-resistant tuberculosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]
Overview
Treatment of tuberculosis must be analysed for relative cost effectiveness of inpatient and outpatient models of care as it will benefit regions where tuberculosis is highly prevalent. Unless there is severe complications it is highly recommended to treat the TB patient in ambulatory care rather than inpatient services.[1]
Cost-effectiveness of therapy
- According to WHO, tuberculosis takes an annual economic toll of around US$12 billion dollars worldwide. 3-4 months of work time are lot due to tuberculosis.
- The average cost of treating a person with TB disease increases with greater resistance.
- Direct costs (in 2010 U.S. dollars) average from $17,000 to treat drug-susceptible TB to $430,000 to treat the most drug-resistant form of the disease (XDR TB). [2]
- When including productivity losses (e.g., lost income) experienced by patients while undergoing treatment, costs are even higher.[2]
 |
- The cost of MDR-TB treatment is upto 100 times more expensive than fully sensitive patients.
- DOTS-Plus is a cost effective approach in areas of assumed poor compliance.
- Reduced price second line drugs must be given to the programs following the guidelines of "Green Light Committee". This could save upto 57.5% of overall budget for TB control. [3]
References
- ↑ Fitzpatrick C, Floyd K (2012). "A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis". Pharmacoeconomics. 30 (1): 63–80. doi:10.2165/11595340-000000000-00000. PMID 22070215.
- ↑ 2.0 2.1 2.2 "CDC Drug-Resistant TB".
- ↑ Gupta R, Kim JY, Espinal MA, Caudron JM, Pecoul B, Farmer PE; et al. (2001). "Public health. Responding to market failures in tuberculosis control". Science. 293 (5532): 1049–51. doi:10.1126/science.1061861. PMID 11463877.